Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -14633.33%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2025 (2025-12-31): -909.38%.
EBITDA MARGIN
-14633.33%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
-293.80%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
-4880.65%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Allarity Therapeutics, Inc.
Market Cap
$15.91M
EBITDA Margin
-14633.33%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$16.22M
EBITDA Margin
-13679.31%
TTM Avg
-8051.39%
3Y Avg
-4553.85%
5Y Avg
-5076.49%
Market Cap
$15.30M
EBITDA Margin
-468.17%
TTM Avg
-602.06%
3Y Avg
-602.06%
5Y Avg
-23374.02%
Market Cap
$16.54M
EBITDA Margin
-579.88%
TTM Avg
-374.35%
3Y Avg
-344.55%
5Y Avg
-411.92%
Market Cap
$16.58M
EBITDA Margin
-82.81%
TTM Avg
-187.23%
3Y Avg
-342.47%
5Y Avg
-369.32%
Market Cap
$15.20M
EBITDA Margin
-29916.57%
TTM Avg
-29916.57%
3Y Avg
-29916.57%
5Y Avg
-29916.57%
Market Cap
$15.20M
EBITDA Margin
-61.90%
TTM Avg
-71.95%
3Y Avg
-80.60%
5Y Avg
-87.82%
Market Cap
$14.28M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | $15.91M | -14633.33% | N/A | N/A | N/A |
| BioCardia, Inc. (BCDA)vs › | $16.22M | -13679.31% | -8051.39% | -4553.85% | -5076.49% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -468.17% | -602.06% | -602.06% | -23374.02% |
| Dyadic International, Inc. (DYAI)vs › | $16.54M | -579.88% | -374.35% | -344.55% | -411.92% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.58M | -82.81% | -187.23% | -342.47% | -369.32% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.20M | -29916.57% | -29916.57% | -29916.57% | -29916.57% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.20M | -61.90% | -71.95% | -80.60% | -87.82% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.62M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.55M | -855.47% | -475.86% | -335.10% | -307.83% |
Gross Margin
107.5%
EBITDA Margin
-14633.3%
Operating Margin
-3939.1%
Net Margin
-3575.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -909.38% |
| 2020-06-30 | -73.69% |
| 2019-12-31 | -4246.78% |
| 2019-06-30 | -7092.17% |
| 2019-03-31 | -4268.03% |
| 2018-12-31 | 23712.09% |
| 2018-09-30 | -72.10% |
| 2018-06-30 | -150.55% |
| 2018-03-31 | -170.21% |
| 2017-12-31 | -242.28% |
| 2017-09-30 | -245.63% |
| 2017-06-30 | -36.54% |
| 2016-12-31 | 1273.03% |
| 2016-09-30 | -852.87% |
| 2016-03-31 | -282.75% |
| 2015-12-31 | -195.86% |
| 2015-09-30 | -803.81% |
